MusclePharm (OTCMKTS:MSLP – Get Rating) and Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
Insider & Institutional Ownership
15.5% of MusclePharm shares are owned by institutional investors. Comparatively, 8.6% of Adamis Pharmaceuticals shares are owned by institutional investors. 60.7% of MusclePharm shares are owned by insiders. Comparatively, 5.9% of Adamis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Get
MusclePharm alerts:
Earnings and Valuation
This table compares MusclePharm and Adamis Pharmaceuticals' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| MusclePharm | $50.04 million | 0.07 | -$12.87 million | ($0.58) | -0.17 |
| Adamis Pharmaceuticals | $2.21 million | 14.59 | -$45.83 million | N/A | N/A |
MusclePharm has higher revenue and earnings than Adamis Pharmaceuticals.
Profitability
This table compares MusclePharm and Adamis Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| MusclePharm | -38.51% | N/A | -169.56% |
| Adamis Pharmaceuticals | N/A | -151.88% | -96.12% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for MusclePharm and Adamis Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| MusclePharm | 0 | 0 | 0 | 0 | N/A |
| Adamis Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
Volatility & Risk
MusclePharm has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
Summary
MusclePharm beats Adamis Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
About MusclePharm
(Get Rating)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
About Adamis Pharmaceuticals
(Get Rating)
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.
